Pharma BD Deal Intelligence

Zydus Lifesciences Limited / Assertio Holdings, Inc.

2026 · Acquisition/Merger · $166M · Pending

Zydus Worldwide DMCC (subsidiary of Zydus Lifesciences) entered a definitive agreement to acquire Assertio Holdings for $23.50/share cash, total consideration ~$166.4M, after Assertio's board deemed Zydus's bid a Superior Proposal over Garda Therapeutics' competing $21.80/share offer (Garda agreement terminated). Adds Assertio's US specialty/oncology supportive-care portfolio (Indocin, Sympazan, Otrexup, Sympan, Rolvedon).

Key facts

• Announced May 13, 2026
• Deal value $166M
• Deal type Acquisition/Merger
• Therapeutic area Acute pain, Lennox-Gastaut syndrome, rheumatoid arthritis, chemotherapy-induced neutropenia
• Indications Acute pain, Lennox-Gastaut syndrome, rheumatoid arthritis, chemotherapy-induced neutropenia
• Key assets Specialty pharma portfolio (Indocin, Sympazan, Otrexup, Rolvedon)

← Browse all deals  ·  How we score deals